Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-03 |
2024-03 |
-0.22 |
N/A |
N/A |
N/A |
2024-03-08 |
2023-12 |
-0.17 |
-0.22 |
-0.05 |
-29.41% |
2023-11-03 |
2023-09 |
-0.18 |
-0.16 |
0.02 |
11.11% |
2023-08-04 |
2023-06 |
-0.21 |
-0.18 |
0.03 |
14.29% |
2023-05-05 |
2023-03 |
-0.18 |
-0.19 |
-0.01 |
-5.56% |
2023-03-13 |
2022-12 |
-0.19 |
-0.16 |
0.03 |
15.79% |
Date |
Firm |
Action |
From |
To |
2023-06-13 |
JonesTrading |
Upgrade |
|
Buy |
2023-05-01 |
Ladenburg Thalmann |
Upgrade |
|
Buy |
2022-08-28 |
Citigroup |
Upgrade |
|
Neutral |
2022-05-19 |
Citigroup |
Upgrade |
|
Neutral |
2021-08-24 |
Citigroup |
Upgrade |
|
Neutral |
2021-04-19 |
Cantor Fitzgerald |
Downgrade |
Overweight |
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2019-02-25 |
BERNSTEIN KAREN |
Director |
20.00K |
Purchase |
2017-05-09 |
DURING MATTHEW M.D. |
President |
4.68M |
Conversion of Exercise of derivative security |
2024-03-17 |
LEVIN JEREMY M |
Chief Executive Officer |
3.65M |
Purchase |
2024-02-21 |
PERONE THOMAS MICHAEL |
General Counsel |
28.13K |
Stock Award(Grant) |
2021-07-13 |
RAKHIT AMIT M.D. |
President |
726.82K |
Sale |
2024-02-21 |
RONA JEFFREY A |
Chief Financial Officer |
28.13K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
BVF Inc. |
6.85M |
22.47M |
9.70% |
2023-06-29 |
EcoR1 Capital, LLC |
6.12M |
20.07M |
8.66% |
2023-06-29 |
Rubric Capital Management LP |
5.45M |
17.86M |
7.71% |
2023-06-29 |
Blackrock Inc. |
3.41M |
11.18M |
4.83% |
2023-06-29 |
Madison Avenue Partners, LP |
3.31M |
10.85M |
4.68% |
2023-06-29 |
Vanguard Group Inc |
2.90M |
9.51M |
4.11% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.85M |
6.07M |
2.62% |
2023-08-30 |
iShares Russell 2000 ETF |
1.20M |
4.04M |
1.70% |
2023-06-29 |
Vanguard Extended Market Index Fund |
695.68K |
2.28M |
0.99% |
2023-07-30 |
Fidelity Small Cap Index Fund |
519.63K |
1.87M |
0.74% |
2023-08-30 |
iShares Russell 2000 Value ETF |
498.03K |
1.68M |
0.71% |
2023-05-30 |
Fidelity Extended Market Index Fund |
271.23K |
960.16K |
0.38% |